Document is current
Any future updates will be listed below
-
Authors
Kanters, Steve
Ball, Graeme
Kahl, Brad
Wiesinger, Adriana
Limbrick-Oldfield, Eve H.
Sudhindra, Akshay
Snider, Julia Thornton
Patel, Anik R.
- License Information
-
More Information
Article History
Received: 24 May 2022
Accepted: 13 January 2023
First Online: 23 January 2023
Declarations
:
: As all data used in this study were publicly available, no ethics approval was required. All methods were carried out in accordance with the relevant guidelines and regulations.
: Not applicable.
: SK: Employment or leadership position: RainCity Analytics; Research funding: RainCity Analytics has received funds from for-profit healthcare companies for research. BK: Consulting: Abbvie, Acerta, Astra Zeneca, ADCT, Celgene, Genentech, Juno, Kite, Morphosys, BeiGene, Pharmacyclics, Janssen, Genmab, Incyte, MEI; Research Funding: Genentech, ADCT, Acerta, Celgene, BeiGene. AW: Employment or leadership position - Kite, A Gilead company; Stock ownership - Kite, A Gilead company. BG: Employment or leadership position: IQVIA. EHLO: Employment or leadership position: RainCity Analytics. AS: Employment or leadership position: Atara Biotherapeutics, Kite Pharma; Stock ownership: Atara Biotherapeutics, Gilead. GB: Employment or leadership position - Kite, A Gilead company; Stock ownership - Kite, A Gilead company. JTS: Employment or leadership position: Kite, A Gilead Company, Stock ownership: Gilead Sciences. AP: Employment or leadership position - Kite, A Gilead company; Stock ownership - Kite, A Gilead company.
